We have expanded our network to include CAR T manufacturing centers in the U.S. as well as a newly constructed biologics plant in Cruiserath, Ireland. GAAP measures are available on the company’s website at 430 E. 29th Street, 14FL, New York, NY 10016 • 212-546-4000 These documents are available from the SEC, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. We are enrolling patients in Phase 2 trials of our Factor XIa inhibitor for secondary stroke prevention and VTE prevention, in collaboration with Janssen Pharmaceuticals, and our research in heart failure is progressing. Bristol Myers Squibb Media:
[email protected] 609-252-3345 Investor Relations: Tim Power 609-252-7509
[email protected] Nina Goworek 908-673-9711
[email protected] These documents are available from the
We are also working to advance policies that support and reward investments in the discovery and development of life-saving medicines. Bristol Myers Squibb (NYSE: BMY), one of the more reliable dividend payers in the pharmaceutical industry, is getting set to hand out its new distribution. forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as
On …
Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Citi’s 15 th Annual BioPharma Virtual Conference, which will be webcast on Tuesday, September 8, 2020. Investors and the general public are invited to listen to a live webcast of the session at Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. contains statements about the company’s future plans and prospects that constitute forward-looking statements for
At Bristol Myers Squibb, we are inspired by our mission – to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We established a clear integration roadmap, designed our new operating model and named several layers of senior leaders. and losses and other specified items.
Our new company has strong commercial franchises in oncology, hematology, immunology and cardiovascular disease, one of the most diverse and promising pipelines in the industry, and highly talented people.Together, we are advancing our mission and our vision to transform patients’ lives through science, and you will see that reflected in our new brand.We start this next chapter at a time when unprecedented scientific breakthroughs are advancing the treatment of disease as never before. About Bristol Myers Squibb. Our symbol, the hand, is a simple, universal expression of healing, of giving and receiving care. We have the financial flexibility to continue to invest in our internal capabilities as well as to support investment in external innovation.These are exciting times for us, and our achievements in 2019 have set the stage for sustained success. In addition, there is no guarantee
We achieve this in part through the Bristol Myers Squibb Foundation, an independent 501(c)(3) charitable organization, which supports community-based programs to address cancer disparities in sub-Saharan Africa, China and Brazil, and in cancer, cardiovascular disease and immunology in the U.S.We are focused on developing transformational medicines that improve upon the current standard of care, and benefit patients, society and payers. This Annual Report